semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-42.0,  Sub Clinical Hypothyroidism Pregnancy Loss Unexplained infertility 2. TSH more than 2.5 and normal T3,T4 levels 3. Negative for Anti-thyroid antibodies  current history of overt hypo or hyperthyroidism 2. recurrent pregnancy loss 3. women having franked causes for infertility like tubal blockage, pelvic inflammatory disease, endometriosis , ,uterine factor 4. Ovarian dysfunction or decreased ovarian reserve 5. abnormal seminal fluid analysis or male factor
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Hypoglycemia Non-Diabetic Gastric Bypass Status Complicating Pregnancy, Birth, or Puerperium GB group: pregnant women with RYGB (n = 20) non-GB group: pregnant women matched on age, prepregnancy-BMI and parity (n = 20) neonates: offspring of abovementioned women (n = 40)  multiple pregnancy age below 18 and above 45 years ongoing smoking and substance abuse severe psychiatric disorder severe chronic disease diabetes women with overt diabetes at (HbA1c ≥ 48 mmol/l and/or fasting p-glucose ≥ 7 mmol/l) women with pre-gestational diabetes (type1 or 2) prior to RYGB women with Gestational Diabetes Mellitus (GDM) in a previous pregnancy will not be excluded
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Primary Hyperparathyroidism Study group, cases with a Primary Hyperparathyroidism Control group consists of healthy adults with the similar demographic characteristics as study group  The presence of osteoarticular deformities Walking with assist device Having a neurological disease that may affect the performance To have significant and irreversible visual deficits The body mass index (BMI) is greater than> 40 kg / m² There is an inability to prevent any of the tests Individuals with cancer history and chemotherapy (over the last 5 years) Plasma creatinine level> 150 µmol / L Use of Cinacalcet or Etalpha Having a history of diabetes mellitus
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Obesity BMI of at least 18.5 kg/m2 Recognizing or celebrating at least two holidays between November and January Access to WiFi  Current eating disorder, history of an eating disorder Involvement in a current weight loss and/or exercise program Pregnancy or nursing Any medications or chronic diseases affecting metabolism or body weight
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Induced Abortion First Trimester Abortion Misoprostol Mifepristone Women are eligible for participation if they have purchased abortion medications (mifepristone-misoprostol) independently at a pharmacy or received them from a clinic for an unwanted pregnancy at less than 9 weeks since her last menstrual period (LMP). She must meet the following Be at least 15 years of age (may vary by country) Have a known LMP of less than 9 weeks No contraindications to medical abortion (list) Willing and able to give informed consent Have a mobile phone of which they are the independent user or be willing to be followed-up in person Willing to be contacted with questions about her abortion by telephone (optional in-person visit) at 3, 10-14 and 30 days following initial contact Resident of country of study  Contraindications to mifepristone-misoprostol Age <15
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thyroid Thyroid Dysfunction Hypothyroidism Pregnancy Early Singleton pregnancy Free of pre-existing thyroid disease That do not use thyroid interfering medication That did not undergo IVF treatment TPOAb negative  Adolescent pregnancy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-39.0,  Infertility, Female Endometrial Diseases Informed consent form (ICF) dated and signed. 2. Age: ≥18 and <40 years old. 3. AFC ≥5 and <20. 4. AMH ≥1.1 ng/mL and <2.5 ng/mL, performed in the 12 months prior to inclusion. 5. Body Mass Index (BMI): ≥18.5 Kg/m2 and <30 Kg/m2. 6. Weight: ≥50 kg and <80 kg. 7. First or second ART cycle or fertility preservation cycle. 8. Regular menstrual cycles (between 22 and 35 days). 9. Two ovaries present. 10. Pregnancy-wish. 11. Planned for single blastocyst transfer  Simultaneous participation in another clinical study. 2. Previous history of poor ovarian response (<4 oocytes retrieved) with a maximal dose of OS (≥300 IU/day) or OHSS, regardless of gonadotropin dose. 3. Known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis). 4. Repeated miscarriages (>2 previous biochemical pregnancies or >2 spontaneous miscarriages). 5. Recurrent implantation failure (>3 failed cycles with good quality embryos). 6. Polycystic ovary syndrome (PCOS). 7. Tumours of the ovary, breast, uterus, pituitary or hypothalamus. 8. Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. 9. Ovarian cysts or enlarged ovaries. 10. Fibroid tumours of the uterus incompatible with pregnancy. 11. Malformations of the reproductive organs incompatible with pregnancy. 12. Primary gonadal failure. 13. Renal impairment defined as estimated glomerular filtration rate of 90 ml/min/1.73 m2 determined by the Modified Diet and Renal Disease (MDRD) equation at screening. 14. Previous antibiotic hypersensitivity reactions (streptomycin and/or neomycin). 15. Risk factors for thromboembolic events, such as a personal or family history, severe obesity or thrombophilia. 16. Moderate or severe hepatic impairment. 17. Untreated and uncontrolled thyroid dysfunction. 18. Current use of oral contraceptive, anti-depressants, anti-psychotics, steroids, anti-epileptics or chemotherapy. 19. Administration of exogenous Estradiol (E2), Progesterone (P4) or gonadotropins in the preceding menstrual cycle. 20. Active female smoking. 21. Acceptors of donated oocytes/embryos. 22. Ongoing pregnancy. 23. Women who have previously enrolled in the trial. 24. Those unable to comprehend the investigational nature of the proposed study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Healthy Caucasian; 2. Male sex; 3. Age: 18-30 4. BMI: 18-25 kg/m2; 5. Normal physical activity levels  Not meeting all 2. Cardiovascular diseases (determined by means of questionnaires, heart rate/blood pressure measurements) 3. Respiratory diseases (including asthma, bronchitis and COPD); 4. Unstable body weight (weight gain or loss > 5 kg in the last three months); 5. Intention to lose or gain body weight (e.g. with caloric restriction or physical activity) 6. Excessive alcohol and/or drug abuse; 7. Hypokalaemia; 8. Hb < 8.4 mmol/L; 9. Epilepsy; 10. Smoking; 11. Renal and/or liver insufficiency; 12. Participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results; 13. Medication use known to hamper subject's safety during the study procedures; 14. Subjects who do not want to be informed about unexpected medical findings; 15. Subjects who do not want that their treating physician to be informed; 16. Inability to participate and/or complete the required measurements; 17. Participation in organised or structured physical exercise; 18. Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk; 19. Hyperthyroidism
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Oligohydramnios Pregnant women between 24-37 weeks of gestation, single fetus, who were diagnosed with an amniotic fluid index at the 5th percentile or below, according to the current gestational age No medical indication for immediate delivery  Refusal to participate in the study A medical recommendation for delivery within two weeks of diagnosis Fetal malformation or proof of fetal infection that known to cause oligohydramnios (eg CMV) Premature rupture of membrane Multiple pregnancy Medical contraindication to the low-salt diet
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Cancer Esophageal Neoplasms Aged 18 years or older Esophagectomy and gastric conduit reconstruction for resectable esophageal (cT1-4aN0-3M0) cancer Postoperative anastomotic leakage according to the ECCG definition [Low 2015]  Esophagectomy for benign disease Emergency resection Patients undergoing extended total gastrectomy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hypertriglyceridemia hypertriglyceridemia (150 mg/dl-900 mg/dl)  Lipid lowering drugs or indication for Lipid lowering drugs LDL-cholesterol > 190 mg/dl Diabetes mellitus
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 14.0-18.0,  Juvenile Osteochondrosis of Spine diagnosis juvenile osteochondrosis (according to the International classification of Diseases ICD M 42 gender: female  any other medical diagnosis
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Obesity in Pregnancy Pregnant women who at their early pregnancy dating scan (optimum time 12 weeks gestation, but with a tolerance of up to 16 full weeks gestation for women who book late) have a BMI of 30 or over and reside in Cwm Taf University Health Board area Aged over 16 Capable of giving informed consent Singleton and multiple pregnancies  Pregnant women who at their early pregnancy dating scan (optimum time 12 weeks gestation, but with a tolerance of up to 16 full weeks gestation for women who book late) have a BMI of less than 29.9 and reside in Cwm Taf University Health Board area Aged under 16 Incapable of giving informed consent Any women who have pre-existing diabetes, or develop gestational diabetes during their pregnancy Any health condition that means the health professional looking after the patient feels would contra-indicate involvement in this programme (e.g. losing the ability to consent during the programme)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.154,  Weight Gain Human Milk Preterm Infants Extremely Low Birth Weight Preterm infants with a birth weight <1000 g  Congenital heart disease Major congenital birth defects Major inborn error of metabolism
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.5-21.0,  Medullary Thyroid Cancer Infantile Myofibromatosis Infantile Fibrosarcoma Papillary Thyroid Cancer Soft Tissue Sarcoma Advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies Evidence of an activating RET gene alteration in the tumor and/or blood Measurable or non-measurable disease Karnofsky (participants 16 years and older) or Lansky (participants younger than 16) performance score of at least 50 Participant with primary CNS tumors or cerebral metastases must be neurologically stable for 7 days prior and must not have required increasing doses of steroids within the last 7 days Adequate hematologic, hepatic and renal function Ability to receive study drug therapy orally or via gastric access Willingness of men and women of reproductive potential to observe conventional and effective birth control  Major surgery within two weeks prior to planned start of LOXO-292 Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292 Active uncontrolled systemic bacterial, viral, fungal or parasitic infection Clinically significant active malabsorption syndrome Pregnancy or lactation Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the participant required a modification to current thyroid medication in the 7 days before start of LOXO-292) Uncontrolled symptomatic hypercalcemia or hypocalcemia Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for participants who will receive LOXO-292 suspension Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s])
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thyroid Cardiac Remodeling, Ventricular STEMI with a confirmed STEMI diagnosis undergoing primary percutaneous coronary intervention (presenting <12h after symptom onset) patients agreed and provided informed consent  past history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass graft past history of heart failure (LVEF<40%) or myocardiopathy or atrial fibrillation past history of thyroid diseases, or were treated with amiodarone, dopamine, or corticosteroids before hospital admission contraindicating to cardiac magnetic resonance imaging
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 1.0-24.0,  B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia B-ALL and MPAL patients must be enrolled on APEC14B1 and consented to studies (Part A) prior to treatment and enrollment on AALL1732. Note that central confirmation of MPAL diagnosis must occur within 7 business days after enrollment for MPAL patients. If not performed within this time frame, patients will be taken off protocol APEC14B1 is not a requirement for B-LLy patients but for institutional compliance every patient should be offered participation in APEC14B1. B-LLy patients may directly enroll on AALL1732 White blood cell count (WBC) for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy) Age 1-9.99 years: WBC >= 50,000/uL Age 10-24.99 years: Any WBC Age 1-9.99 years: WBC < 50,000/uL with Testicular leukemia CNS leukemia (CNS3) Steroid pretreatment White blood cell count (WBC) for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy)  Patients with Down syndrome are not eligible (patients with Down syndrome and B-ALL are eligible for AALL1731, regardless of NCI risk group) With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of B-ALL, MPAL, or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732 Patients who have received > 72 hours of hydroxyurea within one week prior to start of systemic protocol therapy Patients with B-ALL or MPAL who do not have sufficient diagnostic bone marrow submitted for APEC14B1 testing and who do not have a peripheral blood sample submitted containing > 1,000/uL circulating leukemia cells Patients with acute undifferentiated leukemia (AUL) are not eligible For Murphy stage III/IV B-LLy patients, or stage I/II patients with steroid pretreatment, the following additional apply T-lymphoblastic lymphoma Morphologically unclassifiable lymphoma Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma